Sesame Summit 2026 – application open

Lithea Raises €851K for Childhood Bone Cancer Treatment

Childhood bone cancer represents one of oncology’s most challenging frontiers, where traditional treatments often fall short and innovative approaches struggle to secure adequate funding. The European biotech landscape has witnessed renewed investor interest in paediatric oncology, particularly as precision medicine technologies mature and regulatory pathways become clearer.

Swedish biotech Lithea has secured €851,000 in funding to advance its tumour-targeted therapy specifically designed for childhood bone cancer. This funding round signals growing confidence in the company’s approach to addressing unmet medical needs in paediatric oncology, where treatment options remain frustratingly limited.

Lithea Secures Strategic Investment for Tumour-Targeted Innovation

The funding comes from current investors who have doubled down on Lithea’s vision of transforming childhood bone cancer treatment through precision targeting. While the investor composition reflects typical early-stage biotech backing, the continued support demonstrates confidence in the company’s scientific approach and clinical development strategy.

European biotech investors have increasingly focused on companies addressing rare diseases and paediatric conditions, driven by both orphan drug designations and the potential for accelerated regulatory pathways. This funding environment has proven particularly favourable for Swedish biotechs, which benefit from strong academic research institutions and supportive government innovation policies.

The investors’ decision to provide follow-on funding suggests Lithea has achieved key preclinical milestones that de-risk the development pathway. In paediatric oncology, where patient populations are small but medical need is high, investors typically look for strong scientific rationale and clear regulatory strategies before committing capital.

Advancing Precision Medicine in Paediatric Oncology

Lithea’s tumour-targeted therapy represents a shift from conventional chemotherapy approaches towards precision treatments that specifically attack cancer cells while sparing healthy tissue. This approach proves particularly crucial in paediatric patients, where minimising long-term side effects is as important as achieving remission.

The €851,000 will enable Lithea to advance its lead candidate through crucial preclinical development stages, including toxicology studies and manufacturing optimisation required for clinical trials. The company’s focus on childhood bone cancer addresses a significant unmet need, as current treatments often result in long-term complications including growth disorders and secondary cancers.

Sweden’s biotech ecosystem provides Lithea with access to world-class research institutions, experienced clinical investigators, and established regulatory expertise in orphan drug development. The country’s collaborative approach between academia and industry has produced several successful paediatric-focused biotechs, creating a supportive environment for companies like Lithea.

The funding positions Lithea to engage with European regulatory authorities early in development, potentially securing orphan drug designation and accessing expedited review pathways. This regulatory strategy could significantly accelerate the path to clinical trials and eventual market approval.

This investment underscores Europe’s growing strength in precision medicine and demonstrates how targeted funding can advance treatments for rare diseases where commercial incentives have historically been insufficient.

you might also like

Fundraising 3 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.